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oronary Syndromes Following Aspirin Withdrawal
Special Risk for Late Stent Thrombosis
mile Ferrari, MD, Mustapha Benhamou, MD, Pierre Cerboni, MD, Baudouy Marcel, MD
ice, France
OBJECTIVES We sought to determine whether aspirin withdrawal is an encountered situation in coronary
disease patients who relapsed.
BACKGROUND Despite the recognized benefits of aspirin in coronary disease, and because of the threat of
bleeding or poor compliance, aspirin intake is sometimes stopped. It is not known whether
withdrawal of aspirin can be harmful in coronary-disease patients.
METHODS Between September 1999 and April 2002, a total of 1,236 patients hospitalized for acute
coronary syndrome (ACS) were questioned in order to determine whether aspirin intake had
been interrupted.
RESULTS Fifty-one of these ACSs occurred within 1 month after aspirin withdrawal. This represents
4.1% of all coronary events but 13.3% of recurrences. Among those patients who relapsed, the
incidence of ST-segment elevation ACS was higher in those who stopped aspirin when
compared to the 332 patients who did not stop aspirin (39% vs. 18%; p  0.001). Ten (20%)
cases involved a thrombosis of an uncoated stent implanted on average 15.5  6.5 months
previously. Mean delay between aspirin withdrawal and the acute coronary event was 10 1.9
days. Reasons for aspirin withdrawal included minor surgery in 7 cases, fibroscopy in 8 cases,
dental treatment in 13 cases, bleeding in 3 cases, and patient non-compliance in 20 cases.
CONCLUSIONS Our results support the hypothesis that aspirin withdrawal in coronary patients may represent
a real risk for the occurrence of a new coronary event. Many cases involved late uncoated-stent
thrombosis. Assessment of the exact incidence of coronary recurrences after aspirin with-
drawal will need prospective studies. (J Am Coll Cardiol 2005;45:456–9) © 2005 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.11.041American College of Cardiology Foundation
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1spirin is a mandatory treatment for secondary prevention
f coronary artery disease (CAD) and must be continued
hroughout life (1,2). It has not been established, however,
hether withdrawal of aspirin can precipitate coronary
vents. We collected consecutive cases of coronary syn-
romes following aspirin withdrawal in patients with known
oronary disease scheduled to be treated throughout life
ith aspirin.
ETHODS
etween September 1999 and April 2002, patients hospi-
alized for acute coronary syndrome (ACS) were questioned
o discover whether they had stopped any prescribed treat-
ent for coronary disease, especially aspirin. Questions were
sked on admission and then, to avoid errors, repeated twice
uring the patient’s hospital stay, with the assistance of the
amily when necessary.
If aspirin had been interrupted, the exact reason and the
ime since withdrawal were determined with the help of the
ractitioner who had advised the patient to do so. We also
ought to discover whether a substitution therapy had been
iven. As the occurrence of subacute stent thrombosis has
een well described in published reports, patients treated
ith coronary angioplasty and stent implantation during the
From Pasteur Hospital, Nice, France.
Manuscript received October 4, 2004; revised manuscript received November 10,
004, accepted November 20, 2004.revious month were excluded. Moreover, as coronary
yndrome after major surgery is a multi-factorial phenom-
non, those events occurring after major surgery were not
ncluded in the survey. Coronary angiography was per-
ormed in all patients as part of the diagnosis and treatment
f the coronary syndrome. Patients who presented with a
oronary recurrence were compared according to whether
hey had stopped aspirin or not.
tatistical analysis. Comparisons of variables between as-
irin users and those who discontinued aspirin were made
ith a either a chi-square test or Fisher exact test for
ominal variables and with a two-sample t test for contin-
ous variables (Table 1). The type of ACS in patients with
ecurrence according to aspirin intake was compared using a
hi-square test for a four-fold table (Table 2).
ESULTS
uring the 32-month study-period, 1,236 patients with
oronary syndrome (non–ST-segment elevation or ST-
egment elevation) were hospitalized in our center. Among
hese, 383 (31%) were known coronary disease patients and,
onsequently, should have been taking aspirin regularly.
ifty-one new coronary events occurred 1 month after
spirin withdrawal. These 51 cases represent 4.1% (51 of
,236) of all patients hospitalized for a coronary event, and
3.3% (51 of 383) of those who relapsed.
The coronary history that had required the prescription of
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February 1, 2005:456–9 ACS Aspirin Withdrawalspirin in these patients consisted of a previous myocardial
nfarction in 15 cases (29%) and stable angina in 36 cases
71%). Mean delay between diagnosis of the initial coronary
isease requiring aspirin prescription and the recurrent
oronary event after aspirin withdrawal was 4.1  1.2 years.
oronary syndrome following aspirin withdrawal involved
T-segment elevation coronary syndrome in 19 cases (37%)
nd non–ST-segment elevation coronary syndrome in 32
ases (63%). Mean delay between aspirin withdrawal and
he acute coronary event was 10  1.9 days (range 4 to 17
ays). Coronary angiography was performed systematically.
ence, the culprit lesion was identified in all cases. Fur-
hermore, because all patients had been catheterized at least
nce, we were able to compare with the previous condition
f the newly diseased artery segment.
Among patients presenting with ST-segment elevation
oronary syndrome, stent thrombosis was the culprit in 10
ases (19%). All these stents were uncoated, and they had
een implanted a mean 15.5  6.5 months earlier. Among
he remaining 41 cases, coronary angiogram performed on
verage 36 h after the coronary event showed that the culprit
esion had occurred in a previously angiographically normal
egment in 23 cases and in a previously abnormal segment in
8 cases. In all, lesions were: total coronary obstruction in 19
ases (including the 10 cases of stent thrombosis) and
able 1. Characteristics in Recurrent Patients According to
spirin Intake
Aspirin
Withdrawal
(n  51)
No Aspirin
Withdrawal
(n  332) p Value
ge 64  12 63  16 0.43
omen n  10 n  90 0.26
20% 27%
iabetes mellitus n  14 n  100 0.70
27% 30%
ypertension n  10 n  70 0.81
19% 21%
reatinine 2 mg/dl n  4 n  31 1
8% 9%
obacco use n  10 n  39 0.10
(19%) (11.7%)
eta-blockers n  50 n  328 0.51
(99%) (99%)
tatins n  45 n  296 0.84
(88%) (89%)
alcium channel blockers n  4 n  41 0.35
(8%) (12%)
CE inhibitors n  38 n  256 0.68
(75%) (77%)
ata are presented as n (%). p  NS for all variables (continuous variables were
ompared by means of the Student t test and categorical variables by means of the
Abbreviations and Acronyms
ACS  acute coronary syndrome
CAD  coronary artery diseases
hi-square test).
ACE  angiotensin-converting enzyme.on-occlusive lesions, mainly plaque disruption, in the
emaining 32 cases.
Reasons for aspirin discontinuation included: minor sur-
ery in 7 cases, fibroscopy in 8 cases, dental treatment in 13
ases, bleeding in 3 cases, and patient non-compliance in
he remaining 20 cases. Aspirin was not replaced by another
nti-platelet treatment in any of these cases. In four cases,
ther treatments (i.e., beta-blockers [n 4], statins [n 3],
nd angiotensin-converting enzyme inhibitors [n  2])
ere also stopped.
The 383 patients who experienced a recurrence were
ompared according to whether they had discontinued
spirin (n  51) or not (n  332). The main characteristics
f the two groups of patients appear similar (Table 1). In
ontrast, one can note a higher incidence of ST-segment
levation coronary syndrome in the aspirin withdrawal
roup as compared to the group of patients who had a
ecurrence but were still taking aspirin (39% vs. 18%, p 
.001) (Table 2).
ISCUSSION
ur main findings shows that coronary events occurring
fter aspirin withdrawal represent 4% of all coronary events
ospitalized but 13.3% of coronary recurrences. Relapses
ere more often ST-segment elevation ACS in patients
ho had stopped taking aspirin (39% vs. 18%; p  0.001).
inally, 10 of these involved non-coated stent occlusion
ccurring on average 15.5  6.5 months after implantation.
nless there is an obvious contraindication, aspirin is
andatory treatment for patients with coronary disease
1,2).
In biological terms, the platelet inhibition achieved with
spirin, although irreversible for target platelets, lasts until a
ignificant pool of new platelets is synthesized. However,
omplete recovery of platelet aggregation may occur in 50%
f cases by day 3 and in 80% of cases by day 4 (3). Some
nvestigators even suspect the existence of a biological
latelet aggregation “rebound phenomenon.” Beving et al.
4) found that rapid withdrawal of aspirin may cause
bnormally high levels of blood markers reflecting an
ncrease of thromboxane A2 which may have possible
azardous effects in patients with cardiovascular disease.
fter aspirin discontinuation, the recovery of cyclooxygen-
se activity may occur rapidly, with a heterogeneous synthe-
able 2. Type of Acute Coronary Syndrome in Patients With
ecurrence According to Aspirin Intake
Aspirin
Withdrawal
n  51
No Aspirin
Withdrawal
n  332
on–ST-segment elevation coronary
syndrome
31 (61%) 271 (82%)
T-segment elevation coronary
syndrome
20 (39%) 61 (18%)
ata are presented as n (%). p  0.001.is of thromboxane A2 by fresh platelets (5).
1
r
c
o
t
A
d
p
m
b
o
i
h
p
a
e
p
s
i
p
n
s
e
i
p
r
s
(
h
p
p
a
(
(
b
o
p
e
M
o
S
e
i
u
o
w
“
a
a
m
g
l
d
o
c
p
a
c
r
f
m
c
g
c
2
w
m
r
r
s
p
W
p
h
c
a
R
d
R
n
R
458 Ferrari et al. JACC Vol. 45, No. 3, 2005
ACS Aspirin Withdrawal February 1, 2005:456–9From a clinical point of view, Collet et al. (6) published
1 cases of coronary events after aspirin cessation. They also
ecently reported data very similar to ours. Indeed, in their
enter, patients had ceased taking antiplatelet agents (not
nly aspirin) in about 5% of all ACS cases treated. Like us,
hey found a greater incidence of ST-segment elevation
CS in those patients who relapsed after aspirin with-
rawal. Finally, they reported higher mortality in those
atients relapsing when aspirin was discontinued (7).
In addition, our study showed that aspirin withdrawal
ay involve a higher risk for late non-coated stent throm-
osis. Indeed, ten of our cases involved non-coated stent
cclusion occurring on average 15  6.5 months after
mplantation. Although a late-occurring stent thrombosis
as been described in published data (8,9), it remains a rare
henomenon. In our series, late stent thrombosis represents
high proportion (i.e., 20% [10 of 51]) of all coronary
vents occurring after aspirin withdrawal, but a very high
roportion (i.e., 53% [10 of 19]) of coronary total occlu-
ions. Our data should offset the very recent report concern-
ng four cases of late coated-stent thromboses after anti-
latelet withdrawal (10) and suggest that the coating may
ot be the culprit. A non-totally endothelialized coronary
trut may trigger coronary thrombosis when the protective
ffect of aspirin treatment has worn off or whether the stent
s coated or not.
Cessation of aspirin in various scheduled minor surgical
rocedures is beginning to arouse concern in published
eports. An initial study from Kaluza et al. (11) clearly
howed that non-cardiac surgery soon after stent placement
often requiring aspirin withdrawal) was linked to a very
igh rate of adverse events. Subsequent data seemed to
rovide reassurance in cases where non-cardiac surgery was
erformed two months after stent implantation. However,
ntiplatelets were stopped in fewer than 7% of these patients
12). The prospective Pulmonary Embolism Prevention
PEP) study (13) has shown that hip surgery procedures can
e performed on patients taking aspirin, although the excess
f six postoperative transfused bleeding episodes per 1,000
atients assigned aspirin must be placed in balance with the
xpected benefit. Finally, in the setting of bypass surgery,
angano et al. (14) have shown that aspirin cessation is not
nly unnecessary but may even be harmful. The French
ociety of Anesthesiology and Intensive Care has published
xpert recommendations regarding antiplatelet agents dur-
ng the perioperative period. As many questions remain
nresolved, probably the main interest of these expert
pinions is to raise the problem so as to avoid systematic
ithdrawal in low-risk bleeding circumstances. However, in
real life,” owing to the threat of bleeding, patients taking
spirin are often asked by their dentist or surgeon to stop
ntiplatelet medications before a procedure. This “recom-
endation is often made without consulting the cardiolo-
ist or the general practitioner who prescribed the antiplate-
et agents.
Our results support the hypothesis that aspirin with-rawal in coronary patients may represent a real risk for the
ccurrence of a new coronary event. We hypothesize that, in
ertain at-risk patients, discontinuation of aspirin increases
latelet reactivity at a sufficient level to reach the platelet-
ggregation threshold. It is then possible that, in certain
onditions, events such as spontaneous coronary plaque
upture or plaque dissection, which we now know are more
requent than previously thought (15,16), aspirin cessation
ay lead to coronary thrombosis. We did not consider or
ompare hematologic parameters at presentation in either
roup of relapsing patients. Aspirin was discontinued be-
ause of bleeding in 3 cases and due to poor compliance in
0 cases. Hence, we cannot conclude whether aspirin
ithdrawers presented more often with anemia, which
ight have exacerbated outcomes, a hypothesis raised in
ecent published data.
Finally, the assessment of the exact incidence of coronary
ecurrences after aspirin withdrawal will need prospective
tudies. As aspirin withdrawal is obviously not harmful in all
atients, we also need to specify which patients are at risk.
hile awaiting these data, we believe it is necessary to teach
atients, as well as doctors, that aspirin withdrawal may
ave harmful consequences and should be discussed in each
ase. Furthermore, whenever possible, we need to improve
spirin-treatment compliance.
eprint requests and correspondence: Dr. Emile Ferrari, Car-
iology Department, Pasteur Hospital, 30, Avenue de la voie
omaine, Nice, Alpes Maritimes 06200. E-mail: ferrari.e@chu-
ice.fr.
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